Related Experiment Video
Updated: Oct 13, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Long-term immunogenicity and efficacy of a recombinant hepatitis B vaccine in Egyptian children
1Department of Paediatrics, Faculty of Medicine, University of Alexandria, Egypt.
Insights
Egypt's hepatitis B vaccine schedule shows low long-term protection. A new 1, 2, and 9-month schedule and booster doses are recommended for sustained immunity.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Egypt implemented a universal hepatitis B vaccination program in 1992.
- The national schedule involved vaccine administration at 2, 4, and 6 months of age.
Purpose of the Study:
- To assess the long-term immunogenicity and efficacy of the hepatitis B vaccine schedule used in Egypt.
- To evaluate antibody concentrations and seroprotection rates in children vaccinated at different time points.
Main Methods:
- A cohort of 180 children vaccinated with the hepatitis B vaccine (2, 4, 6 months schedule) was studied.
- Participants' time since last vaccination ranged from 1 month to 5 years.
- Hepatitis B surface antigen (HBsAg), anti-hepatitis B core (anti-HBc), and anti-hepatitis B surface (anti-HBs) antibody levels were measured.
Main Results:
- A high seroprotection rate (93.3%) was observed shortly after vaccination.
- However, initial anti-HBs concentrations were low and declined rapidly over time.
- No participants exhibited clinical hepatitis or HBsAg, and most had negative anti-HBc results.
Conclusions:
- The 2-month interval between the second and third hepatitis B vaccine doses may compromise long-term immunity.
- Booster vaccinations are recommended for all previously vaccinated children.
- A revised vaccination schedule (1, 2, and 9 months) is proposed for improved long-term protection.
Abstract:
In 1992, Egypt adopted a hepatitis B vaccine schedule at 2, 4 and 6 months of age. We evaluated the long-term immunogenicity and efficacy of vaccination using this schedule in 180 children whose time lapse since last vaccination varied between 1 month and 5 years. None of the participants had clinical hepatitis, HBsAg was not detected in any participant and all but one had negative results for anti-HBc test. Although a high seroprotection rate (93.3%) was elicited 1 month after vaccination, there were low initial anti-HBs concentrations and both declined rapidly over time. Thus, the short interval (2 months) between the second and third doses of vaccine is less desirable in the long term. We recommend booster inoculations for all previously vaccinated children and a new vaccination schedule at 1, 2 and 9 months.
Related Concept Videos
Vaccinations
Vaccines
Poliomyelitis
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Hepatitis
